- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00353977
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
A Pilot Trial of an Accelerated Immunization Schedule With ALVAC-pp65 (vCP260) for Inducing CMV-Specific Immunity in Stem Cell Allotransplant Donors and Healthy Volunteers
This study will evaluate the safety and effectiveness of a new vaccine, ALVAC-pp65, in boosting immunity to cytomegalovirus (CMV) infection in stem cell transplant donors. CMV is a member of the herpesvirus group, which includes herpes simplex virus types 1 and 2, varicella-zoster virus (which causes chickenpox), and Epstein-Barr virus (which causes infectious mononucleosis). Most adults are infected with CMV, but a healthy immune system keeps the virus in check, so that it does not cause harm. In people with a weakened immune system, such as transplant recipients, the virus can become reactivated. Medications for treating the infection may cause low blood counts and kidney damage, and, in some cases, the virus may cause death. The ALVAC-pp65 vaccine is intended to improve immunity against CMV in stem cell donors and thereby prevent its reactivation in recipients. It is made from a virus that ordinarily infects canaries. The virus is weakened so that it cannot infect the person who receives it, and it is modified to carry a copy of a CMV gene called pp65. This gene instructs cells to make CMV proteins that the vaccine recipient's immune system can produce antibodies to, thus conferring immunity to the disease.
Persons 18 years of age or older who are scheduled to donate stem cells for a patient in an NIH protocol and who are not allergic to eggs, egg products, or other vaccines, may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood tests.
Participants receive three vaccinations one week apart beginning at least 3 weeks before the scheduled stem cell donation. They are observed for 30 minutes after each vaccination to look for any immediate side effects of the vaccine. Approximately 3 tablespoons of blood are drawn before each vaccination and 1 week after the last vaccination to evaluate vaccine safety. Blood samples are also collected at the screening evaluation, 3 weeks after the start of vaccination, and 3 months after the last vaccination to check for CMV immunity.
Participants keep a diary, recording any reactions to the vaccine and any change in medications. They are contacted by telephone for follow-up 3 months after the last vaccination to report any additional symptoms.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cytomegalovirus (CMV) infection is a major complication following allogeneic stem cell transplantation (SCT). The risk of CMV infection after SCT is inversely related to the number of CMV-specific cytotoxic T-lymphocytes (CTLs) present in the allograft. CMV-specific lymphocytes can be readily detected and quantified in the blood by sensitive in vitro techniques that measure T cell cytokine secretion following antigen stimulation. A previous phase I clinical trial has demonstrated that CMV-specific T cells can be safely generated in normal CMV-seronegative (naive) subjects after immunization with the CMV vaccine, ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine Sanofi Pasteur (formerly known as Aventis Pasteur, Lyon, France).
We propose a clinical trial to evaluate an accelerated immunization schedule with the same vaccine. Study participants will be 1) SCT donors and their matched recipients participating in intramural NIH allogeneic SCT protocols and 2) CMV sero-negative normal volunteers. Donors will receive two or three immunizations prior to allograft collection, and followed for 45 days for the development of CMV immunity. Normal volunteers will receive two or three immunizations and followed similarly to the donors. CMV sero-positive subjects will receive two immunizations; CMV sero-negative subjects will receive three. Transplant (SCT) recipients will be evaluated for incidence of CMV infection and disease.
The study is designed as a two-stage phase II trial with stopping rules at each stage. The primary outcome measures are the effectiveness of the vaccine in (a) generating cellular immunity in CMV-seronegative (naive) donors or CMV sero-negative normal volunteers and (b) boosting the cellular immune response in CMV-seropositive (sensitized) donors and healthy volunteers. Secondary outcomes include the clinical safety profile of the vaccine in vaccine recipients and the incidence of CMV infection/disease in transplant recipients. Since the cellular immune response to CMV is a standard model for immune reconstitution post transplant, our study may also provide important information on the feasibility of immunizing stem cell transplant donors with other microbial and tumor vaccines.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA: VACCINE RECIPIENT
- Under evaluation for enrollment as a donor on a stem cell transplant protocol at the NIH Clinical Center, Or
- CMV sero-negative or sero-positive healthy volunteer
- Age greater than or equal to 18 years, but less than or equal to 80 years
- Ability to comprehend the investigational nature of the study and provide informed consent
- All subjects (men and women) must agree to practice abstinence or effective contraception during the study period
- Baseline laboratory evaluations are within normal limits
- For woman, negative urinary pregnancy test
- Informed consent from transplant recipients obtained
- INCLUSION CRITERIA:
STEM CELL TRANSPLANT RECIPIENT
- Under evaluation for enrollment as a recipient on a stem cell transplant protocol at the NIH
- Age greater than or equal to 18 years, and less than or equal to 75 years
- Ability to comprehend the investigational nature of the study and provide informed consent
- EXCLUSION CRITERIA:
VACCINE RECIPIENT
- History of severe adverse reaction or allergy to any vaccine
- Known or suspected allergies to vaccine constituents - eggs, mono-sodium glutamate or neomycin
- Acute febrile illness within the 72 hours preceding the vaccination
- History of any immunosuppressive disease or major chronic disorder
- History of treatment with immunosuppressive medications in the past 6 months
- Pregnant or breast feeding
- Enrolled or planning to enroll in another drug or vaccine clinical trial during the study period (other than the stem cell transplant when applicable)
- EXCLUSION CRITERIA:
STEM CELL TRANSPLANT RECIPIENT
- There are no exclusion criteria for stem cell transplant recipients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ALVAC-CMV (vCP260) Vaccinated group
Patients who were vaccinated with ALVAC-CMV (vCP260)
|
ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle. Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10. Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cellular Immune Response in Vaccine Recipients
Time Frame: Day 45
|
Evaluate the efficacy of an accelerated ALVAC-pp65 immunization schedule in generating cytomegalovirus (CMV)-specific immunity in seronegative transplant donors and healthy volunteers (HV) and augmenting CMV-specific immunity in seropositive transplant donors.
|
Day 45
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis. 1994 Dec;170(6):1410-7. doi: 10.1093/infdis/170.6.1410.
- Bevan IS, Daw RA, Day PJ, Ala FA, Walker MR. Polymerase chain reaction for detection of human cytomegalovirus infection in a blood donor population. Br J Haematol. 1991 May;78(1):94-9. doi: 10.1111/j.1365-2141.1991.tb04388.x.
- Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood. 1999 Jan 1;93(1):394-8.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 040198
- 04-H-0198 (Other Identifier: National Heart Lung and Blood Institute)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Infections
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMaternal Cytomegalovirus Infections | Cytomegalovirus CongenitalUnited States
-
University of Sao Paulo General HospitalCompletedCytomegalovirus DiseaseBrazil
-
Mayo ClinicCompletedCytomegalovirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus InfectionUnited States, France, Germany, Italy, Japan, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Institut PasteurCompletedCongenital Cytomegalovirus InfectionFrance
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionsUnited States, Australia, Canada, Finland, Israel, Russian Federation, Spain
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
Clinical Trials on ALVAC-CMV (vCP260)
-
John SampsonCompleted
-
National Institute of Allergy and Infectious Diseases...National Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute... and other collaboratorsCompleted
-
Beckman Coulter, Inc.Terminated
-
Daping Hospital and the Research Institute of Surgery...The First Affiliated Hospital of Anhui Medical University; LanZhou University; Beijing 302 Hospital and other collaboratorsWithdrawnAcute Respiratory Distress Syndrome | Conventional Mechanical Ventilation | High Frequency Oscillation VentilationChina
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
-
U.S. Army Medical Research and Development CommandNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingHIV InfectionsThailand
-
University of NebraskaWithdrawnCMV Viral Loads in Seropositive Renal Transplant RecipientsUnited States
-
University Health Network, TorontoCanadian National Transplant Research ProgramCompletedCytomegalovirus ViraemiaSpain, Canada
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
Hospital de Niños R. Gutierrez de Buenos AiresNot yet recruitingCongenital CytomegalovirusArgentina